Andrew McConaghie is a Senior Writer at Informa. He focuses on themes such as medicine and healthcare, alternative medicine, diagnostics, and business economics, with particular attention to topics like the coronavirus, Moderna, and the FDA. Andrew's work has been featured in Citeline, showcasing his expertise in the intersection of healthcare and business.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Andrew McConaghie's articles primarily focus on the healthcare and pharmaceutical industries, with a particular emphasis on scientific advancements, drug development, and industry-specific announcements. His coverage attributes indicate a reliance on press releases and data citations.
Given his focus, Andrew is likely to be interested in pitches from individuals with expert knowledge in pharmaceuticals, biopharmaceuticals, drug development processes, CAR-T therapy or immunology. He may also be receptive to pitches related to significant industry-specific announcements or groundbreaking scientific developments within the healthcare sector.
Although no specific geographic focus is mentioned for Andrew’s coverage area, it would still be beneficial for potential sources to have international expertise given the global nature of the pharmaceutical industry.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Andrew McConaghie
After setbacks and a withdrawn filing, Dato-DXd is back on track for a potential second-line approval later this year in EGFR-mutant lung cancer. The partners are still counting on success in first line lung cancer and breast cancer treatment
The company believes its WVE-007 can improve on GLP-1 agonists by preserving muscle mass while also not interfering with the pleasure of eating. Promising mouse data are still to be confirmed in humans, however.
The company is moving quickly to bring its antibody oligonucleotide conjugates to patients in three separate muscular dystrophy diseases, causing unease for its rivals.
After ditching its clinical-stage ex vivo candidate in December, the CRISPR-based company is starting all over again with a focus on in vivo therapies and upregulating beneficial genes.
Three parallel Phase III studies of iclepertin aiming to improve cognitive function have failed but optimism about other schizophrenia treatments is growing.
Septerna is the best performer of newly launched firms from Q4, with more initial public offerings fuelled by potential interest rate cuts hoped for in 2025.
By: Andrew McConaghie
The potentially groundbreaking approach would use immunotherapy or targeted therapies against pre-cancerous cells to prevent cancer from developing at all.
By: Jan By, Andrew McConaghie
Flagship Pioneering has unveiled a new collaboration with Cambridge UK, to find synergies with academics and hospitals in the scientific hotspot, and create new biotech start-ups. Scrip spoke to Flagship about its plans.
A lack of big pharma licensing deals and IPOs created problems, but newer UK biotech companies moved ahead in 2024 thanks to increased venture capital funding, finds a new report from the BIA.
By: Jan By, Andrew McConaghie
The company believes its divalent small interfering RNA technology can boost CNS penetration and durability and aims to have its first two programs in the clinic by 2026.
(833) 317-6278 
